Sarcoma Drug Pipeline: 223 Assets by Phase

How many sarcoma drugs are in each phase of development?

Douglas Insights counts 16 sarcoma candidates in Phase III, 7.2% of the 223 assets in development; Phase II holds 67 and Phase I holds 140.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each sarcoma asset appears in exactly one row. The 583 trials still recruiting or running carry 50% of the 1,176 registered trials in scope.

Which approved sarcoma medicines are still in trials?

1 medicines already on the market are still being tested in sarcoma Phase IV trials; Anlotinib has the most, with 21 registered trials.

Post-approval sarcoma trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many sarcoma trials are recruiting patients now?

323 sarcoma trials are recruiting patients and 76 more have not started recruiting yet, out of 1,176 interventional trials in scope; together they make up 34% of the trial base.

Terminated, suspended and withdrawn sarcoma trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the sarcoma pipeline?

Amgen leads the sarcoma pipeline with 8 candidates; the top 5 sponsors hold 14% of the 223 assets, and 141 sponsors run at least one.

Industry sponsors lead 345 of the 1,176 sarcoma trials (29%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the sarcoma pipeline?

Mechanism and drug-type classification for the 223 sarcoma candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What sarcoma trial readouts are coming next?

31 sarcoma candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many sarcoma readouts fall in each quarter?

41 sarcoma candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 11, due in Q4 2026.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most sarcoma trials?

United States hosts the most sarcoma trials, with sites in 717 of the 1,176 studies (61%); trials in scope run in 66 countries in all.

A multinational sarcoma trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are sarcoma drugs being tested?

717 of the 1,176 sarcoma trials (61%) have a site in the United States, 290 (25%) in Europe and 180 (15%) in China; 173 of the 223 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational sarcoma trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the sarcoma pipeline since the last update?

This is the first edition of the sarcoma pipeline count, dated 3 Oct 2026. The next refresh is due by 1 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the sarcoma pipeline?

Douglas Insights read 1,176 interventional trials registered on ClinicalTrials.gov for the conditions "sarcoma", "soft tissue sarcoma" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 223 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the sarcoma pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage